Ai, X., Yu, Y., Zhang, T., Yi, T., Li, M., Yao, W., Han, L., Sun, L., Liu, A., Mei, Q., Han, G., Zhang, Z., Li, Y., Li, L., Zheng, L., Fang, Y., Luo, Y., Lv, B., Zhu, A. X., Lu, S. (2026). Updated results of the randomized phase 2 dose optimization study of alveltamig (ZG006), a trispecific T cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with advanced small cell lung cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8109